BioCentury | Jan 20, 2014
Company News

ACT Biotech, Eddingpharm deal

...Eddingpharm acquired exclusive, worldwide rights to develop and commercialize oncology compounds telatinib, ACTB1003 and ACTB1010 from...
...have a timeline for the trial start. Eddingpharm hopes to begin Phase I testing of ACTB1003...
...growth factor receptor ( FGFR ) gene amplification or mutation, including breast and lung cancer. ACTB1003...
BioCentury | May 9, 2011
Emerging Company Profile

ACT: ACTing selectively

...to put more resources towards the rest of its pipeline. ACT's next most advanced program, ACTB1003...
BioCentury | Feb 1, 2010
Clinical News

ACTB1003: Phase I start

...evaluate oral ACTB1003 in about 20 patients. ACT Biotech Inc. , San Francisco, Calif. Product: ACTB1003...
Items per page:
1 - 3 of 3